Banner Slide

Going further to bring better days to even more people with cancer

Building better todays for more patients worldwide

At Helsinn, we’ve made it our mission to improve the everyday lives of patients. We’ve been a family-run pharmaceutical company since we were founded over 40 years ago, guided by our values of integrity, respect and with a 360-degree approach to quality that runs through everything we do. Today, we’re leading the way in supportive care in cancer, and are committed to building better todays for more patients worldwide.

Our Business

The Helsinn Group is one of the world's leading supportive cancer care companies, with a comprehensive portfolio of medicines and therapies helping to improve the lives of patients in countries around the world.

Learn more

Corporate Social Responsibility and Sustainability

Sustainability is becoming an increasingly central part of Helsinn’s culture and business strategy. Integrity, quality and respect have always been at the core of our business, but increasingly, organisations are aware that they function as part of an ecosystem to which they have a responsibility. Care for the communities in which we operate, and stewardship of our environment, are as important to our long-term future as the economic bottom line.

Learn more

Our Products

The strength of the Helsinn model is reflected in the product candidates that we have transformed into sustainable market successes.

Learn more

Our Building Blocks

News & Events

Helsinn at ESMO 2017 in Madrid

Madrid, Spain 8-12 September 2017

Read more

Helsinn will attend at ASCO 2017

Chicago per sitointro

The "2017 ASCO Annual Meeting -Making a Difference in Cancer Care" will take place in Chicago, Illinois, on June 2-6 201...

Read more

Helsinn Attendance at J.P. Morgan Annual Healthcare Conference

Helsinn is at the 35th Annual JP Morgan Healthcare Conference taking place from January 9 to 13, 2017 in San Francisco, ...

Read more

Helsinn Group and MEI Pharma Report Prolongation of Survival Results from Phase ...

Phase 2 study results presented at American Society of Hematology Annual Meeting on Saturday, December 3, 2016

Read more

Helsinn Integrative Care Announces 510(K) FDA Clearance for Medical Device Xonri...

Logo HIC RGB Sito

Helsinn Integrative Care, Helsinn’s business unit focused on evidence-based, non-pharmaceutical cancer supportive care p...

Read more

HELSINN ADVANCED SYNTHESIS 2016/2017 EDUCATION SCHOLARSHIPS FOR 11 STUDENTS IN ...

Borse di Studio HAS 2016 Foto gruppo 2

On Friday November 18, 2016, 11 students received the Helsinn AdvancedSynthesis 2016/2017 Education Scholarship of 5.000...

Read more